HyQ FDA Approval Status
HyQ (immune globulin and recombinant human hyaluronidase) is an investigational combination immunoglobulin product intended for the treatment of patients with primary immunodeficiencies.
In August 2012, Baxter International Inc. announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) advising the company that the New Drug Application (NDA) for HyQ had not been approved.
Development Timeline for HyQ
|Aug 20, 2012||Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA|
|Aug 2, 2012||Baxter Confirms Receipt of Complete Response Letter on HyQ|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.